AU2003250825A1 - Inhibitors of glycoprotein vi - Google Patents

Inhibitors of glycoprotein vi

Info

Publication number
AU2003250825A1
AU2003250825A1 AU2003250825A AU2003250825A AU2003250825A1 AU 2003250825 A1 AU2003250825 A1 AU 2003250825A1 AU 2003250825 A AU2003250825 A AU 2003250825A AU 2003250825 A AU2003250825 A AU 2003250825A AU 2003250825 A1 AU2003250825 A1 AU 2003250825A1
Authority
AU
Australia
Prior art keywords
fusion protein
glycoprotein
inhibitors
provides
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003250825A
Other languages
English (en)
Other versions
AU2003250825A8 (en
Inventor
Andreas Bultmann
Meinrad Gawaz
Sabine Gruner
Steffen Massberg
Gotz Munch
Bernhard Nieswandt
Mario Peluso
Martin Ungerer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Procorde GmbH
Original Assignee
Procorde GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procorde GmbH filed Critical Procorde GmbH
Publication of AU2003250825A8 publication Critical patent/AU2003250825A8/xx
Publication of AU2003250825A1 publication Critical patent/AU2003250825A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
AU2003250825A 2002-06-07 2003-06-05 Inhibitors of glycoprotein vi Abandoned AU2003250825A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02012742A EP1369128A1 (en) 2002-06-07 2002-06-07 Inhibitors of glycoprotein VI and their therapeutic use
EP02012742.9 2002-06-07
PCT/EP2003/005919 WO2003103662A2 (en) 2002-06-07 2003-06-05 Inhibitors of glycoprotein vi

Publications (2)

Publication Number Publication Date
AU2003250825A8 AU2003250825A8 (en) 2003-12-22
AU2003250825A1 true AU2003250825A1 (en) 2003-12-22

Family

ID=29433140

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2003250825A Abandoned AU2003250825A1 (en) 2002-06-07 2003-06-05 Inhibitors of glycoprotein vi
AU2003236704A Expired AU2003236704B2 (en) 2002-06-07 2003-06-05 Glycoprotein VI - FC fusion protein for treating vascular disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2003236704A Expired AU2003236704B2 (en) 2002-06-07 2003-06-05 Glycoprotein VI - FC fusion protein for treating vascular disorders

Country Status (13)

Country Link
US (1) US7514543B2 (OSRAM)
EP (4) EP1369128A1 (OSRAM)
JP (1) JP4722480B2 (OSRAM)
CN (1) CN1668721B (OSRAM)
AT (1) ATE346095T1 (OSRAM)
AU (2) AU2003250825A1 (OSRAM)
CA (1) CA2488630C (OSRAM)
DE (1) DE60309865T2 (OSRAM)
DK (1) DK1860118T3 (OSRAM)
ES (2) ES2527717T3 (OSRAM)
SI (1) SI1511770T1 (OSRAM)
WO (2) WO2003104282A2 (OSRAM)
ZA (1) ZA200409776B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7531178B2 (en) 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
GB0511590D0 (en) * 2005-06-07 2005-07-13 Procorde Gmbh Anti-thrombotic agents
US20070071744A1 (en) 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
US7645592B2 (en) 2004-04-29 2010-01-12 Otsuka Pharmaceutical Co., Ltd. Glycoprotein VI antibodies and methods of use thereof
AU2005243193B2 (en) * 2004-04-29 2011-01-27 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein VI and methods of producing these antibodies
ES2534288T3 (es) 2004-08-03 2015-04-21 Innate Pharma Composiciones terapéuticas contra el cáncer que seleccionan como objetivo 4Ig-B7-H3
EP1824979A2 (en) * 2004-12-10 2007-08-29 Trigen GmbH Methods, products and uses involving platelets and/or the vasculature
FR2884831B1 (fr) * 2005-04-22 2007-08-10 Merck Sante Soc Par Actions Si Methode de criblage de composes inhibiteurs de la mtp
WO2006117910A1 (ja) 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. 抗血小板膜糖蛋白質ⅵモノクローナル抗体
JP5224707B2 (ja) * 2005-04-28 2013-07-03 持田製薬株式会社 抗血小板膜糖蛋白質ｖｉモノクローナル抗体
CA2606450A1 (en) * 2005-04-28 2006-11-09 Mochida Pharmaceutical Co., Ltd. Anti-platelet membrane glycoprotein vi monoclonal antibody
US20110045504A1 (en) * 2005-12-22 2011-02-24 Noriaki Kume Prognostic Prediction Method for Acute Coronary Syndrome
RU2010121878A (ru) * 2007-10-31 2011-12-10 Оцука Фармасьютикал Ко., Лтд. (Jp) Применения ингибитора гликопротеина vi (gpvi)
EP2352815B1 (en) * 2008-12-04 2016-02-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for producing platelets
EP4311863A3 (en) * 2009-05-15 2024-04-10 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp alpha- cd47 interaction
EP2397495A1 (en) * 2010-06-21 2011-12-21 Sanofi Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
EP2336188A1 (en) * 2009-12-18 2011-06-22 Sanofi-Aventis Novel antagonist antibodies and their Fab fragments against GPVI and uses thereof
TW201132759A (en) * 2009-12-18 2011-10-01 Sanofi Aventis Novel antagonist antibodies and their FaB fragments against GPVI and uses thereof
EP2377888A1 (en) * 2010-04-07 2011-10-19 Corimmun GmbH Fusion protein
HRP20192013T1 (hr) 2012-12-17 2020-02-07 Trillium Therapeutics Inc. Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama
WO2014098242A1 (ja) * 2012-12-20 2014-06-26 藤森工業株式会社 血小板凝集能の総合的評価方法
EP3424957A1 (en) 2017-07-03 2019-01-09 advanceCOR GmbH Fusion protein
CN110964119A (zh) * 2019-12-05 2020-04-07 沣潮医药科技（上海）有限公司 抗疟二聚体免疫粘附素、药物组合物和用途
US11858962B2 (en) * 2020-02-06 2024-01-02 Boehringer Ingelheim Vetmedica Gmbh Polypeptides useful for detecting anti-rhabdovirus antibodies

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5156840A (en) * 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
ZA887365B (en) 1987-10-02 1990-05-30 Genentech Inc Adheson variants
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6406697B1 (en) * 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5525491A (en) * 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
GB9806806D0 (en) 1998-03-30 1998-05-27 Univ Cambridge Tech Peptides and uses thereof
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
GB9810999D0 (en) * 1998-05-21 1998-07-22 Goken Joop Materials and methods relating to the expression of genes
CA2372515C (en) 1999-05-07 2015-12-01 Merck Patent Gesellschaft Mit Beschraenkter Haftung Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US6245527B1 (en) * 1999-06-30 2001-06-12 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding glycoprotein VI and recombinant uses thereof
US7291714B1 (en) * 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
WO2001016321A1 (en) 1999-09-01 2001-03-08 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1224942A1 (en) 2001-01-23 2002-07-24 Bernhard Dr. Nieswandt Use of JAQ1 (monoclonal antibody anti GPVI) as a medicament for the protection against thrombotic diseases
EP2070939B1 (en) 2001-05-25 2014-04-02 Duke University Modulators of pharmacological agents
WO2003008454A2 (en) 2001-07-18 2003-01-30 Merck Patent Gmbh Glycoprotein vi fusion proteins
GB0130543D0 (en) 2001-12-20 2002-02-06 Univ Cambridge Tech Human antibodies and their use
GB0130832D0 (en) 2001-12-22 2002-02-06 Univ Reading Modulation of the activity of the platelet endothelial cell adhesion molecule-1 (pecam-1)
GB0211750D0 (en) 2002-05-22 2002-07-03 Ouwehand Willem Abnormal blood conditions
US7531178B2 (en) * 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
EP1369128A1 (en) 2002-06-07 2003-12-10 Procorde GmbH Inhibitors of glycoprotein VI and their therapeutic use
EP1538165A1 (en) 2003-12-03 2005-06-08 Procorde GmbH Inhibitors of glycoprotein VI based on monoclonal antibody hgp 5c4

Also Published As

Publication number Publication date
CA2488630C (en) 2011-07-05
WO2003104282A8 (en) 2004-04-29
EP1511770A2 (en) 2005-03-09
WO2003103662A2 (en) 2003-12-18
JP2006512894A (ja) 2006-04-20
AU2003250825A8 (en) 2003-12-22
EP1860118B1 (en) 2014-12-31
SI1511770T1 (sl) 2007-04-30
DE60309865T2 (de) 2007-10-18
WO2003104282A3 (en) 2004-10-14
ES2276078T3 (es) 2007-06-16
JP4722480B2 (ja) 2011-07-13
ATE346095T1 (de) 2006-12-15
CA2488630A1 (en) 2003-12-18
US7514543B2 (en) 2009-04-07
US20050079541A1 (en) 2005-04-14
CN1668721B (zh) 2012-11-14
AU2003236704A1 (en) 2003-12-22
AU2003236704B2 (en) 2010-07-08
EP1511480A2 (en) 2005-03-09
EP1860118A2 (en) 2007-11-28
EP1860118A3 (en) 2008-07-30
EP1511770B1 (en) 2006-11-22
DK1860118T3 (en) 2015-02-09
WO2003104282A2 (en) 2003-12-18
WO2003103662A3 (en) 2004-11-04
ZA200409776B (en) 2007-02-28
DE60309865D1 (de) 2007-01-04
EP1369128A1 (en) 2003-12-10
ES2527717T3 (es) 2015-01-28
CN1668721A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
AU2003250825A8 (en) Inhibitors of glycoprotein vi
DK1144607T3 (da) Fremgangsmåde til præsentation af (poly)peptider/proteiner på bakteriofage partikler via disulfidbindinger
PT2360176E (pt) Expressão híbrida e em série de proteínas derivadas de neisseria
UA95438C2 (ru) Биспецифические антитела, которые замещают функциональные белки
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
CY1112787T1 (el) Πολλαπλομερη του υποδοχεα κυτοκινης ζcytor17
PL336306A1 (en) Proteinous fusions of tgf-beta ii type receptor with a constant immunoglobulin area
DE60043626D1 (de) Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
EA200600042A1 (ru) Способы образования дисульфидных связей и гликозилирования белков и реагенты, применяемые в этих способах
ATE459004T1 (de) Ligand für den formylpeptidrezeptorähnlichen- 2 (fprl2) g protein gekoppelten rezeptor und dessen anwendung
AU2003251238A1 (en) Modulation of platelet adhesion based on the surface exposed beta-switch loop of platelet glycoprotein ib-alpha
DE60141657D1 (de) Verfahren zur Reinigung von stark anionischen Proteinen
DE60230147D1 (de) Verfahren zur überwachung und modulierung von proteinfaltung
DK0794255T3 (da) Fremgangsmåde til spaltning af kimært protein ved anvendelse af processeringsenzym
JP2008530988A5 (OSRAM)
ATE414164T1 (de) Verfahren zur kontrolle der spaltung mit ompt protease
ATE316096T1 (de) Verfahren zum carboxygruppenschutz der säuren c- terminalen aminosäuren bei chemischer verknüpfung von oligopeptiden
IL157309A0 (en) Method for the purification of a non-immunoglobulin protein
WO2004007536A3 (en) Interactions of the epstein-barr virus protein ebna1, and uses thereof
ATE511644T1 (de) Neues screening-verfahren
AU2003202489A1 (en) Screening method
ATE431835T1 (de) Verfahren zum schutz von thiolgruppen in antikörpern
AU2003280359A1 (en) Phosphoamidase assay

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase